The ablation of Pgrmc2 had no effect on mast cell recruitment, indicating that the ability of a Pgrmc2 deficiency to slow the progression of endometrial cancer on a Pten haploinsufficient background does not stem from changes in mast cell recruitment or degranulation. This evidence concerns the gene PTEN and endometrial cancer.